Hepatitis C in hemodialysis patients

Table 4 Studies with combined Ribavirin plus Interferon-α therapy in hepatitis C virus infected hemodialysis patients

Combinationtherapy	Ref.	No. of patients	Dose	Duration	SVR (%)	Withdrawal rate (%)
IFN-α + RBV	Mousa et al[78]	20	3 MU (IFN) + 200 mg (RBV) 3 times per week	24 wk (n = 9)	67	0
			3 MU (IFN) + 200 mg (RBV) 3 times per week	48 wk (n = 11)	36	0
PegIFN-α + RBV	Rendina et al[79]	35	135 μg/wk (Peg-IFN-a-2a) + 200 mg/qd (RBV)	48 wk (gtp 1)	97	14
				24 wk (non-gtp 1)
PegIFN-α + RBV	Carriero et al[80]	14	135 μg/wk (Peg-IFN-a-2a) + 200 mg/qd(RBV)	48 wk	29	71
PegIFN-α + RBV	Hakim et al[81]	15	135 μg/wk (Peg-IFN-a-2a) + 200 mg/wk to 3 times per week (RBV)	48 wk	7	33
PegIFN-α + RBV	Liu et al[82]	35	135 μg/wk (Peg-IFN-a-2a) + 200 mg/qd (RBV)	48 wk (gtp 1)
				24 wk (non-gtp 1)	60	17

IFN-α: Interferon-α; PegIFN-α: Pegylated interferon-α; RBV: Ribavirin.